Physician
Hematology
Shivaani R. Kummar, MB
|
|
Give Review
Shivaani Kummar works in the field of Hematology. Shivaani Kummar is a published doctor. She has 87 papers published. The most current publication "In-111 labeled octreotide imaging of a primary carcinoid lesion undetected by conventional imaging studies in a patient with "chronic pancreatitis"."
Publications
- Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast...
- Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.
- Application of molecular profiling in clinical trials for advanced metastatic Cancers.
- A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal Cancer.
- Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
- Translational research in oncology-10 years of progress and future prospects.
- Cabozantinib-Induced Thyroid Dysfunction: A Review of Two Ongoing Trials for Metastatic Bladder Cancer and Sarcoma.
- Validation of a Hypoxia-Inducible Factor-1α Specimen Collection Procedure and Quantitative ELISA in Solid Tumor Tissues.
- Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
- Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
- Wee1 kinase as a target for Cancer therapy.
- Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.
- Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.
- Molecular targets in Cancer therapy.
- A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell Carcinomas, and pheochromocyt...
- Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor Tissues.
- Safety and feasibility of targeted agent combinations in solid tumours.
- Antiangiogenic approaches for the treatment of advanced synovial Sarcomas.
- A phase I combination study of olaparib with Cisplatin and gemcitabine in adults with solid tumors.
- LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
- Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenoCarcinoma.
- Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-betaI.
- In-111 labeled octreotide imaging of a primary carcinoid lesion undetected by conventional imaging studies in a patient with "chronic pancreatitis".
- Cytokeratin staining for primary and metastatic colorectal Cancer.
- Positron emission tomography for the evaluation of patients with colorectal Cancer.
- Metastatic hepatocellular Carcinoma.
- Unusual sites of colorectal Cancer metastasis.
- Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal Cancer.
- Management of small bowel adenoCarcinoma.
- Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
- Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
- A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
- A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal Cancer.
- Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors.
- Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
- Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck Cancer.
- Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1? in advanced solid tumors.
- Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.
- Role of Phase 0 trials in drug development.
- Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
- Phase 0 trials: expediting the development of chemoprevention agents.
- Foreword. Poly(ADP-ribose) polymerase inhibitors in clinical development.
- Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
- Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung Cancer receiving sorafenib.
- Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
- Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
- AdenoCarcinoma of the small bowel: changes in the landscape?
- The statistics of phase 0 trials.
- Evaluation of multiple targeted agents as potential therapies for hepatocellular Carcinoma (HCC). Foreword.
- Topics in clinical pharmacology: renal, gastrointestinal, and pain management.
- Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells.
- Advances in the treatment of metastatic colorectal Cancer.
- Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced mal...
- Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors.
- A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
- Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
- Metastatic pancreatic adenoCarcinoma: current standards, future directions.
- Targeted therapy for advanced non-small cell lung Cancers: historical perspective, current practices, and future development. Foreword.
- Next generation oncology drug development: opportunities and challenges.
- Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
- Multiple Myeloma. Foreword.
- Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
- DNA methylation: its role in Cancer development and therapy.
- The observation that changes in DNA methylation potentially play a role in neoplastic transformation has existed for nearly 30 years. Foreword.
- Histone deacetylase inhibitors in Cancer therapy.
- Treatment of recurrent metastatic colon Cancer in the age of modern adjuvant therapy.
- The mammalian target of rapamycin (mTOR). Foreword.
- Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation.
- Designing phase 0 Cancer clinical trials.
- Phase 0 clinical trials: conceptions and misconceptions.
- Phase 0 clinical trials in Cancer drug development: from FDA guidance to clinical practice.
- Role of insulin-like growth factor-1R system in colorectal carcinogenesis.
- Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
- Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection.
- Compressing drug development timelines in oncology using phase ''0'' trials.
- Drug development in oncology: classical cytotoxics and molecularly targeted agents.
- Targeting epigenetic abnormalities with histone deacetylase inhibitors.
- Targeting VEGF in Cancer therapy.
- Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrome...
- Non-small-cell lung Cancer vaccine therapy: a concise review.
- False elevations in prostate-specific antigen levels affecting patient management.
- Prostate Cancer metastasis to supraclavicular lymph node.
- Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast canc...
- A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic Cancer.
- Primary non-Hodgkin''s lymphoma of the liver.
Conditions Treated
- Carcinoma in Situ
- Cervical Cancer
- Soft Tissue Sarcoma
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Helpful Reviews
Similar Doctors
|
|
Louis M. Staudt |
|
|
Sawa Ito |
|
|
Raffit Hassan, MB |
|
|
Dr. Geraldine H. O'Sullivan, MD |
|
|
Dr. Leslie G. Ford, MD |
|
|
Dr. David C. Van Echo, MD |
|
|
Dr. Arash Mohtashamian, MD |
|
|
Dr. Daniel Godwin Wright, MD |
|
|
Dr. John E. Janik, MD |
|
|
Dr. James J. Goedert, MD |
|
|
Dr. Frederick A. Dorr, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alice P. Chen, MD |
|
|
Dr. Charles D. Bolan Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanjeeve Balasubramaniam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margaret E. Rick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frederic J. Kaye, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph V. Boccia, MD
This Doctor is OpenDoctor Recommended.
|